Coronary Microvascular Dysfunction Market Insights report from DelveInsight provides a thorough understanding of the Coronary Microvascular Dysfunction Market size by treatment, epidemiology, emerging therapies, market share of the various therapies, and the current and forecasted Coronary Microvascular Dysfunction Market size from 2019 to 2032 divided into the 7MM (the USA, EU5 (Germany, France, Italy, Spain, and the UK), and Japan) regions.
Coronary Microvascular Dysfunction Overview
Coronary microvascular dysfunction (CMD) is a heart disease that affects the walls and inner lining of tiny coronary artery blood vessels that branch off from the larger coronary arteries. It describes the abnormality in the microcirculation leading to an inadequate vasodilatory response, or a pathological vasoconstrictive response, to physiological or pharmacological stress. Moreover, it carries an increased risk of adverse cardiovascular clinical outcomes.
Download Sample Report- https://www.delveinsight.com/sample-request/coronary-microvascular-dysfunction-market
Regions covered in the report
Key highlights of the Coronary Microvascular Dysfunction Market Report
Coronary Microvascular Dysfunction Epidemiology Insights
As per Vancheri et al. (2020), CMD is functionally expressed as reduced coronary flow reserve (CFR), which is the maximum increase in coronary blood flow above the resting value after pharmacological coronary vasodilatation. Reduced CFR due to functional and/or structural abnormalities of the microcirculation has been reported in about 50% of patients with chronic coronary syndromes and up to 20% of those with acute coronary syndromes, in the absence of epicardial coronary flow obstruction.
Coronary Microvascular Dysfunction Epidemiology Segmentation in the 7MM
Do you want to know more information related to report? If yes, visit here- https://www.delveinsight.com/sample-request/coronary-microvascular-dysfunction-market
Coronary Microvascular Dysfunction Treatment Market
Coronary Microvascular Dysfunction treatment starts with lifestyle modification and risk factor control. Management of risk factors includes statins and angiotensin converting enzyme (ACE) inhibitors, in hypertensive patients, which improve endothelial dysfunction represent a first line of treatment in patients with microvascular angina. Furthermore, therapeutically lowering blood pressure can improve CFR, but excess lowering of diastolic blood pressure attenuates the benefit. Insulin sensitizer, metformin, has been shown to improve endothelial function.
Coronary Microvascular Dysfunction Market Insights
Medications like aminophylline and fasudil are under investigation. Aminophylline a nonselective adenosine-receptor antagonist, blocks the mediation of nociception. It is postulated to benefit CMD by attenuating the excess dilation of the microvasculature in a relatively well-perfused area, thus shunting more blood to poorly perfused areas. Fasudil, a rho kinase inhibitor, reduces smooth muscle cell hypercontraction and is being researched currently and has potential for CMD. Furthermore, given that impaired cardiac nociception maybe involved in CMD, tricyclic antidepressants can be considered, as they are thought to have a modulatory effect on norepinephrine uptake and anticholinergic effect that can cause analgesia. Imipramine has been shown to reduce the frequency of pain, but one of the studies did not show any improvement in quality of life, likely because of its significant side effects.
Coronary Microvascular Dysfunction Emerging Therapy Assessment
CMD is highly prevalent and has significant unmet clinical need. More research and large-scale studies are therefore urgently needed to address this important health condition. Currently, pipeline for CMD is limited only comprising of few players; hence, the indication hold enormous opportunities to bring novel innovation to cater to the unmet needs of patients with CMD.
Request Sample Report- https://www.delveinsight.com/sample-request/coronary-microvascular-dysfunction-market
Table of Content
1. Key Insights
2. Coronary Microvascular Dysfunction Executive Summary
3. Coronary Microvascular Dysfunction Competitive Intelligence Analysis
4. Coronary Microvascular Dysfunction: Market Overview at a Glance
5. Coronary Microvascular Dysfunction: Disease Background and Overview
6. Patient Journey
7. Coronary Microvascular Dysfunction Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Coronary Microvascular Dysfunction Unmet Needs
10. Key Endpoints of Coronary Microvascular Dysfunction Treatment
11. Coronary Microvascular Dysfunction Marketed Products
12. Coronary Microvascular Dysfunction Emerging Therapies
13. Coronary Microvascular Dysfunction: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Coronary Microvascular Dysfunction Market Outlook
16. Access and Reimbursement Overview
17. KOL Views
18. Coronary Microvascular Dysfunction Market Drivers
19. Coronary Microvascular Dysfunction Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Coronary Microvascular Dysfunction Market Report Highlights
Why should you buy this report?
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/